Status:
UNKNOWN
Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease
Lead Sponsor:
Avidia
Conditions:
Crohn's Disease
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine whether C326, a new inhibitor of IL-6, is safe in patients with Crohn's disease.
Detailed Description
Determination of safety is the most important goal of this first study with C326. Other goals of the study are to examine: * pharmacokinetics (change in serum concentrations over time), * biological ...
Eligibility Criteria
Inclusion
- Adults 18 - 65
- Stable, moderately active Crohn's Disease
- Otherwise in generally good health
Exclusion
- Variety of concurrent medical conditions
- Various concomitant medications
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
End Date :
September 1 2007
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00353756
Start Date
September 1 2006
End Date
September 1 2007
Last Update
October 11 2006
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
QPharm
Brisbane, Queensland, Australia
2
Center for Clinical Studies
Melbourne, Victoria, Australia